R.I.-based Bolden Therapeutics, Inc. secures $1.5M in pre-seed convertible note funding. This financing provides important support to enable Bolden to advance its preclinical development of antisense oligonucleotides to promote neurogenesis.
Read also – MA-based 3Daughters Secures Over $2M in Seed Funding
The round was led by Resolute Venture Partners, and included investments from Slater Technology Fund, Lifespan Vision Ventures, and multiple angel investors.
Johnny Page, Co-Founder and CEO of Bolden Therapeutics said, “We are very excited to have the support of our investors in pursuing our mission,” “These funds, along with the $1.8M Bolden has received in National Institutes of Health Small Business grants, will enable us to advance our preclinical candidates and generate important in vivo data that will hopefully inform our path towards clinical development.”
Bolden’s scientific co-founders, Dr. Justin Fallon and Dr. Ashley Webb have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons (neurogenesis) in the adult brain.
Read also – CA-based PowerSchool Acquired Allovue
The company is developing antisense oligonucleotides to modulate this genetically-validated target, and Bolden has begun testing these antisense oligonucleotide candidates in vivo.
Justin Fallon, PhD, Scientific Co-Founder and Chair of Bolden Therapeutics’ Scientific Advisory Board said, “Over the past few years, several important advancements have led to major progress in the treatment of Alzheimer’s disease and other neurological conditions, It is clear that many brain diseases which were once thought to be untreatable are now becoming addressable. We are working to develop our neurogenesis-promoting antisense oligonucleotide candidates to become effective treatments for these disorders.”
Charlie Polsky, MD, Executive Chairman of Bolden Therapeutics said, “This financing will help Bolden build on its already exciting body of data to inform how and in which diseases our candidate interventions might be used, We look forward to using these resources to better understand how these candidates may one day improve the lives of patients suffering from brain diseases.”
ABOUT BOLDEN THERAPEUTICS, INC.
Bolden Therapeutics, Inc., is a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of central nervous system illnesses such as Alzheimer’s disease.
Read also – Conn.-based Kusari Secures $8m in Pre-Seed & Seed Funding
